Prometic to conduct PBI-4050 ’s Phase II/III trial for IPF in US

Canada-based Prometic Life Sciences has secured investigational new drug (IND) approval from the US Food and Drug Administration (FDA) to evaluate its drug candidate PBI-4050 in a Phase II/III clinical trial to treat idiopathic pulmonary fibrosis (IP …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news